Detalles de la búsqueda
1.
A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China.
Expert Rev Clin Pharmacol
; 16(3): 267-273, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36877089
2.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis.
Ther Adv Med Oncol
; 15: 17588359231171038, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37223263
3.
Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective.
Front Oncol
; 13: 1272586, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38169749
4.
Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma.
Ther Adv Med Oncol
; 14: 17588359221116604, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35958872
5.
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis.
Ther Adv Med Oncol
; 14: 17588359221122733, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36147862
6.
Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis.
Ther Adv Med Oncol
; 14: 17588359221130501, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36312816
Resultados
1 -
6
de 6
1
Próxima >
>>